| CVD | cardiovascular disease; cerebrovascular disease; collagen vascular disease; color-vision-deviant |
|---|---|
| CVF | cardiovascular failure; central visual field; cervicovaginal fluid; cobra venom factor |
| CVFn | cardiovascular function |
| CVM | cardiovascular monitor; cerebral venous malformation; cyclophosphamide, vincristine, and methotrexat... |
| CVRD | cardiovascular-renal disease |
| contraceptive agents, male | Chemical substances or agents with contraceptive activity in males. Use for male contraceptive agents in general or for which there is no specific heading. (12 Dec 1998) |
|---|---|
| haematologic agents | Drugs that act on blood and blood-forming organs and those that affect the haemostatic system. (12 Dec 1998) |
| haematologic, gastrointestinal, and renal agents | A collective grouping for agents that act on the haematopoietic, gastrointestinal, and renal systems. (12 Dec 1998) |
| cryoprotective agents | Substances capable of protecting against injury due to freezing, as glycerol protects frozen red blood cells. (12 Dec 1998) |
| hepatitis agents, gb | Proposed members of the family flaviviridae. Gbv-b causes hepatitis in tamarins and possibly humans, and is the putative aetiological agent of a non-(a-e) hepatitis, gb hepatitis. (12 Dec 1998) |
| protective agents | Synthetic or natural substances which are given to prevent a disease or disorder or are used in the process of treating a disease or injury due to a poisonous agent. (12 Dec 1998) |
| histamine agents | Drugs used for their actions on histaminergic systems. Included are drugs that act at histamine receptors, affect the life cycle of histamine, or affect the state of histaminergic cells. (12 Dec 1998) |
| serotonin agents | Drugs used for their effects on serotonergic systems. Among these are drugs that affect serotonin receptors, the life cycle of serotonin, and the survival of serotonergic neurons. (12 Dec 1998) |
| hypoglycaemic agents | Agents which lower the blood glucose level. (12 Dec 1998) |
| spermatocidal agents | Chemical substances that are destructive to spermatozoa used as topically administered vaginal contraceptives. (12 Dec 1998) |
| spermatogenesis-blocking agents | Chemical substances which inhibit the process of spermatozoa formation at either the first stage, in which spermatogonia develop into spermatocytes and then into spermatids, or the second stage, in which spermatids transform into spermatozoa. (12 Dec 1998) |
| sperm immobilizing agents | Chemical substances with sperm immobilizing activity used as topically administered vaginal contraceptives. (12 Dec 1998) |
| neuromuscular agents | Drugs used for their actions on skeletal muscle. Included are agents that act directly on skeletal muscle, those that alter neuromuscular transmission (neuromuscular blocking agents), and drugs that act centrally as skeletal muscle relaxants (muscle relaxants, central). Drugs used in the treatment of movement disorders are anti-dyskinesia agents. (12 Dec 1998) |
| neuromuscular blocking agents | Drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. They can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarising agents) or noncompetitive, depolarising agents (neuromuscular depolarising agents). Both prevent acetylcholine from triggering the muscle contraction and they are used as anaesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc. (12 Dec 1998) |
| neuromuscular depolarising agents | Drugs that interrupt transmission at the skeletal neuromuscular junction by causing sustained depolarisation of the motor end plate. These agents are primarily used as adjuvants in surgical anaesthesia to cause skeletal muscle relaxation. (12 Dec 1998) |